OUR LATEST UPDATE:  Biocoat Acquires Chempilots to Expand its Biomaterial Platform… READ MORE

Biocoat Names Scott Cramer As Chair Of Company’s Board of Directors

July 30, 2018

Cramer will lead the Biocoat Board of Directors, which provides guidance and direction to the growing organization.

Horsham, PA. July 09, 2018 — Biocoat, Inc. has appointed former Accriva Diagnostics President and CEO Scott Cramer as Chair of its Board of Directors.

The Biocoat Board of Directors provides guidance and direction to the growing Horsham, PA-based company, which develops and licenses biomaterial coatings for medical devices that are custom engineered to meet specific clinical design parameters.

“The election of Scott Cramer as Chairman of the Biocoat Board of Directors gives our growing organization a level of insight and experience that will help us achieve our aggressive growth and product development goals throughout the United States and Europe,” said Jim Moran, President and CEO, Biocoat. “I look forward to working with Scott and the rest of the Board as we expand our product offerings and implement our market expansion strategy.”

About Scott Cramer
Cramer has an extensive history in the medical device and diagnostics field. He is skilled in driving change within organizations by helping executive leaders establish a high-performance workplace and implementing appropriate growth strategies. In late 2013, Cramer became the President and CEO of Accriva Diagnostics. While at Accriva, Cramer restructured, moved the company to San Diego, and grew sales to almost $100 million in 2016. In January 2017, Accriva sold to WerfenLife for $380 million.

In previous roles, Cramer served as President and CEO of Novasys Medical Inc., from 2010 to 2012 and of Bacchus Vascular Inc., from 2007 to 2009. He has been an Entrepreneur in Residence at Warburg Pincus and currently serves on the Investment Advisory Committee for Venture Investors LLC.

“Biocoat has already done an excellent job positioning itself as a leader in the field for biomaterial coatings and is the clear choice in the neurovascular space,” said Cramer. “I am thrilled to be working with the rest of the Board and Biocoat leadership to guide the evolution of the company.”

About Biocoat, Inc.

Biocoat, Inc. develops and licenses biomaterial coatings for medical devices that are custom engineered to meet specific clinical parameters. The company specializes in supplying lubricious hydrophilic coatings for medical devices to original equipment manufacturers and contract manufacturers. Biocoat is also able to provide coating services to aspiring medical device companies that require assistance with manufacturing.

To learn more about Biocoat visit www.biocoat.com, call 215-734-0888 or connect on LinkedIn and Twitter.

Share this article

Biocoat Team

Related News

Related Resources

Want to hear the latest from us?

Sign up to our email list to stay up to date.

We care about the protection of your data. Read our Privacy Policy.

Let’s Connect

Our team of engineers and clinical experts would be glad to have a discussion about your project and its requirements.
By submitting this form you acknowledge that you have reviewed our privacy policy and understand how we are using your information. reCAPTCHA helps prevent automated form spam. The submit button will be disabled until you complete the CAPTCHA.